Tucatinib versus placebo added to trastuzumab and capecitabine for patients with previously treated HER2+metastatic breast cancer with brain metastases (HER2CLIMB)
Authors
Lin, N. U.Murthy, R. K.
Anders, C. K.
Borges, V. F.
Hurvitz, S. A.
Loi, S.
Abramson, V. G.
Bedard, P. L.
Oliveira, M.
Zelnak, A. B.
DiGiovanna, M.
Bachelot, T.
Chien, A. J.
O'Regan, R.
Wardley, Andrew M
Muller, V.
Carey, L. A.
McGoldrick, S. M.
An, G.
Winer, E. P.
Affiliation
Dana-Farber Cancer Institute, Boston, MAIssue Date
2020